Related Experiment Videos
Neonatal outcome after treatment with ritodrine: a controlled study
American Journal of Obstetrics and Gynecology
|October 1, 1983
Summary
Maternal ritodrine treatment did not significantly impact infant Apgar scores or neurological condition. However, potential jaundice risks warrant further investigation in newborns exposed to ritodrine.
Area of Science:
- Neonatal health
- Pharmacology
- Obstetrics
Background:
- Ritodrine is a tocolytic agent used to prevent premature labor.
- Maternal administration of ritodrine may potentially affect neonatal outcomes.
- Assessing neonatal condition after maternal ritodrine exposure is crucial for understanding drug safety.
Purpose of the Study:
- To evaluate the neonatal condition of infants born after maternal ritodrine treatment.
- To compare neonatal outcomes between infants exposed to ritodrine in utero and a control group.
- To identify any potential adverse effects of ritodrine on newborns.
Main Methods:
- A cohort of 82 infants born at term following maternal ritodrine treatment was studied.
- A matched control group of infants was used for comparison.
- Neonatal assessments included umbilical pH, Apgar scores, head circumference, and neurological examination.
Main Results:
- No statistically significant differences were observed in umbilical pH, Apgar scores, head circumference, or neurological condition between the ritodrine-exposed and control groups.
- While not statistically significant, a potential icterogenic (jaundice-causing) effect of ritodrine was noted.
Conclusions:
- Neonatal outcomes such as Apgar scores and neurological status appear unaffected by maternal ritodrine treatment.
- Further research is recommended to investigate the potential icterogenic effect of ritodrine in newborns.
- Ritodrine's safety profile in neonates requires continued evaluation, particularly regarding jaundice risk.